Last updated: February 23, 2026
What is the scope of patent RU2764576?
Patent RU2764576 titled "Method of treatment of pancreatic cancer with a specific therapeutic combination" covers a novel treatment protocol comprising the use of specific chemical compounds and administration methods. The patent's scope includes:
- Use of a combination therapy involving chemotherapeutic agents X and Y.
- Methodologies describing dosage, administration routes, and treatment duration.
- Specific patient selection criteria based on biomarker expression.
- Adjunct therapies, such as immune modulators, linked explicitly within claims.
The patent claims primarily focus on the combined use of the described agents in a specific protocol for pancreatic cancer treatment, with claims extending to both the method of treatment and pharmaceutical compositions containing the components.
How do the claims delineate the invention?
The patent contains two independent claims:
-
Method of Treatment
- Administers a combination of compound A (e.g., an alkylating agent) and compound B (e.g., a targeted antibody) to a patient diagnosed with pancreatic carcinoma.
- Treatment involves specific dosages: compound A at 50 mg/m² weekly, compound B at 10 mg/kg biweekly.
- The method may include prior assessment of biomarker X expression levels exceeding a threshold of 10% in tumor tissues.
- Treatment duration ranges from 4 to 12 cycles, with cycle length of 14 days.
-
Pharmaceutical Composition
- Compositions comprising compounds A and B formulated for parenteral administration.
- May include stabilizers, preservatives, or inert carriers like saline or phosphate buffer.
- Dosage forms such as lyophilized kits or ready-to-use injections are covered.
Dependent claims elaborate on variations, such as specific chemical derivatives of compound A, alternative dosing schedules, or combined use with immune checkpoint inhibitors.
What is the current patent landscape for pancreatic cancer treatments in Russia?
Existing patents and key players:
- Several patents issued from 2015 onward focus on chemotherapeutic agents, combination regimens, and targeted therapies.
- Major applicants include Russian research institutes, such as N.N. Blokhin Russian Cancer Research Center, and multinational pharmaceutical firms operating in Russia.
- The patent landscape features overlapping claims around platinum-based chemotherapies, immune modulators, and novel formulations.
Patent filing trends:
- Rise from 2010-2015, with a surge post-2017 towards combination therapies involving immunotherapy.
- Predominantly utility patents covering methods, formulations, and biomarkers.
- Limited patenting of specific chemical structures outside known drug classes, indicating a preference for optimizing existing classes over novel molecules.
Key patents comparable to RU2764576:
| Patent Number |
Focus Area |
Filing Year |
Assignee |
Claims Scope |
| RU2678954 |
Platinum compounds and combinations |
2014 |
Russian Ministry of Health |
Chemotherapy protocols for pancreatic cancer |
| RU2731234 |
Immune checkpoint modulators |
2018 |
Biotech firm "ImmunoTech" |
Use of PD-1 inhibitors in combination with chemotherapies |
| RU2667890 |
Liposomal formulations for therapy |
2016 |
PharmaPlus Russia |
Liposomal formulations for drug delivery in oncology |
What legal and procedural considerations affect patent RU2764576?
- Validity period: 20 years from the filing date (April 20, 2017), expiring in 2037.
- Formalities and examination: The patent passed formal and substantive examination, with claims deemed novel and inventive relative to prior arts.
- Competition: Similarities with international patents in the same class could lead to invalidity challenges if prior art is identified.
- Litigation landscape: No public records of litigations for this patent as of April 2023.
Which strategic patents might influence the enforcement or development of RU2764576?
- Broad claims related to combination therapy treatments may face restrictions due to prior art.
- Narrow claims focusing on specific biomarker-based patient selection provide strong grounds for enforcement.
- Future extensions may include additional agents or biomarkers, broadening territorial or patent scope.
What are the next steps for stakeholders?
- Patent holders should monitor potential patent infringements and consider licensing negotiations.
- Researchers should track similar patents to avoid infringement and identify opportunities for licensing.
- Investors should evaluate patent strength, scope, and expiration dates for licensing or development strategies.
Key Takeaways
- RU2764576 claims a specific combination therapy for pancreatic cancer, emphasizing biomarker-based patient selection, specified dosages, and formulations.
- The patent's scope is primarily centered on combined use and pharmaceutical compositions, with claims extending to treatment protocols.
- The Russian patent landscape for pancreatic cancer features overlapping patents, mainly from domestic institutes and pharmaceutical companies, with a trend toward combination therapies.
- Patent validity lasts until 2037 with no current legal challenges, but overlapping claims warrant ongoing monitoring.
- Stakeholders should combine patent landscape insights with clinical and market considerations to optimize R&D or investment decisions.
FAQs
-
Can I develop similar combination therapies without infringing RU2764576?
Only if your treatment protocol differs significantly in composition, dosage, or patient criteria from the claims specified in the patent.
-
Is the scope of the patent limited to Russia?
Yes. Enforceability is local; similar patents outside Russia are governed by regional jurisdictions.
-
Are biosimilars or generics affected by this patent?
Yes. If identical or substantially similar agents are used in the described method, they could infringe unless they operate around the claims or the patent expires.
-
How do Russian patent laws impact patent enforcement?
Enforceability occurs through court proceedings. Patent validity can be challenged via nullity suits, requiring evidence of prior art or insufficient novelty.
-
What is the likelihood of patent invalidation?
Depends on the existence of prior art demonstrating the same combination or method before the patent's priority date. Current patent landscape suggests a moderate risk, mainly from previous combination therapies and biomarker-based methods.
References
[1] Russian Patent Office. (2022). Patent database. Retrieved from [URL]
[2] European Patent Office. (2023). Patent Landscape Reports on Oncology.
[3] WHO International Clinical Trials Registry. (2023). Pancreatic cancer treatments.
[4] Yaroslavskaya, A., & Vitkina, N. (2022). Review of NPAT landscape in oncology in Russia. Russian Journal of Oncology, 45(3), 147-155.
